Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from Lepu Biopharma Co. Ltd. Class H ( (HK:2157) ).
Lepu Biopharma Co., Ltd. reported significant financial growth for the first half of 2025, achieving a revenue of approximately RMB465.9 million, which is 3.5 times higher than the same period in 2024, and marking its first profitable period with a profit of RMB29.3 million. The company is advancing its drug pipeline, with MRG003 nearing approval for NPC treatment and other key candidates like MRG004A and MRG006A progressing through various clinical trial stages, indicating a strong focus on expanding its market presence in oncology.
The most recent analyst rating on (HK:2157) stock is a Hold with a HK$8.50 price target. To see the full list of analyst forecasts on Lepu Biopharma Co. Ltd. Class H stock, see the HK:2157 Stock Forecast page.
More about Lepu Biopharma Co. Ltd. Class H
Lepu Biopharma Co., Ltd. is a joint stock company incorporated in China, operating in the biopharmaceutical industry. The company focuses on the development and commercialization of innovative drugs, particularly in the field of oncology, with products like PUYOUHENG (Pucotenlimab Injection) and several other drug candidates advancing through clinical trials.
Average Trading Volume: 33,888,487
Technical Sentiment Signal: Buy
Current Market Cap: HK$17.64B
For an in-depth examination of 2157 stock, go to TipRanks’ Overview page.